Sure you can. And when every other biotech is going through the same thing, you should stay mum. Because it has nothing to do with your company specifically. Suck it up.
This situation, while possible, isn't likely. Most drugs on the market do not have severe adverse side events. If they did, the majority wouldn't be on the market given the risk/reward for non-life threatening conditions wouldn't justify such a thing. Suggesting that it would be a miracle for eteplirsen to not have an SAE is just silly.
Also, it doesn't matter or not if market expects an SAE to occur eventually. If one does, the stock will get crushed. Don't believe me? Look at ENTA today. And that was for an SAE that was already known to exist. So your food for thought is nice, but it's not going to prevent the stock from cratering. It's akin to people thinking that if they remove their stock from margin that it won't suffer from a short attack. Naive thinking...
What the eff are you talking about? Are you completely nuts and/or clueless? That's, you know, illegal; not to mention stupid. Please tell me you aren't actually this unintelligent.
I think you mean give him a raise. His timing was impeccable. He deserves kudos.
Please name 10 s-mid biotechs that have raised over $100 million through a non-dilutive secondary. Thanks in advance.
SRPT is incorporated in Delaware for a reason. Vultures, if they are out there, won't be successful.
I don't think capitulation is all that close for the sector as a whole, although I do think a bounce is due here very soon, particularly in SRPT.
It's always tough to pick a bottom, so I'm certainly not going to hold onto $250 as the bottom, but I am going to pay attention to price. Every uptrend gets smacked right back down. Until we have a clear sign that the trend has changed, I'm avoiding biotechs. It's going to take more than one or two candles to signal that.
We're in a biotech bear market. Look at what happened to RLYP and MACK today. Both of which had good news.
Notice how the market is ripping yet again today and biotech sector is still red? That's a big red flag, folks, and there have been plenty in the past few weeks.
Don't be surprised if IBB hits $250 in the coming months. Just saying. Be smart and hedge or hold cash.
My gawd. What a joke of a report. To actually suggest that eteplirsen has no clinical effect is laughable.
With biotech where it is right now, I'd rather buy on an uptick than catch a falling knife. There will still be room for further advancement once things settle and good news starts pouring in. I'm not worried about catching a double anymore.
I think longterm SRPT is fine, and still hold some January 2017 $10 and $15 leaps that I bought at the end of last year/beginning of this year. But not buying stock until I see clear strength in the sector.
I think folks who've primarily invested in biotech for the past 6 years need to be a little more objective, and this relates to SRPT as well. I see so many people on Twitter (and here on the board) talking about all of the great deals in biotech. They've been so accustomed to buying the dip that they're failing to realize just how immensely damaged the biotech market is right now. In reality, are things so bad? Probably not. But reality doesn't matter much in the market. Sentiment does, and big money has been unloading their biotechs left and right. It is a risk off sector now and probably for awhile.
Think about it. What triggered the drop in the first place? The drug pricing issue. With the political debates still at their infancy for this next presidential run, do you really think that issue is going to go away anytime soon and do you really think it will suddenly stop having an effect on the biotech market? Be careful of buying "good deals." If you're sitting on piles of cash and don't mind waiting it out longterm, by all means, have at it, but those falling knives that you're trying to catch could very well lose another 30% or more. And yes, this includes SRPT. Catalysts don't mean much when a sector is in a bear market. Just ask RLYP.
Just my two cents. There's nothing wrong with sitting on cash.
What is going to take for investors to look at the big picture? Starfe is right. The odds that drisa gets approved are much higher than not. You have to look at everything, and not just the data. Northera was a complete #$%$ drug that recently got approved. Why? Because of patient advocacy groups. And if you think advocacy for that drug was strong, then wait until you see the turnout for the drisa Adcom.
STOP UNDERESTIMATING THE POWER OF ADVOCACY, EVEN IN THE FACE OF A QUESTIONABLE DRUG.
You have absolutely no clue what you are talking about.
The company attempted once to submit the NDA, and it was filed by the FDA on that attempt.
The Adcom panel will have more than 9 reviewers.
You really ought to know these basic facts before posting.
Unless unexpected, positive news is imminent, I doubt it. Short-term bottom, maybe. Bottom won't be in until biotech sector finds a bottom. That doesn't appear to be anywhere in sight yet.